All In Biotech

Drug Trial Radar · NCT03830125

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

88

Actual

Start

Feb 13, 2019

Primary completion

Nov 24, 2019

Study completion Nov 24, 2019

Sponsor

Lead sponsor
Bridge Biotherapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
KCRN Research, LLC
First posted
Feb 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • BBT-877, Single doseDrug

    Single dose of BBT-877, 5 dose levels, oral capsule

  • Placebo groupDrug

    Placebo matched to BBT-877, oral capsule

  • BBT-877, Multiple dosesDrug

    Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and severity of treatment emergent adverse events (TEAEs)Time frame: 7 days after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.